Skip to main content

Table 1 Basic characteristics of included RCTs

From: Comparative efficacy of treatments for patients with knee osteoarthritis: a network meta-analysis

Author, year, country Disease degree Treatments Size Age Male (%) BMI Dosage No. of injection Follow-up
Yu, 2018, China KL grade I–IV PRP 104 46.2 48.10   8 ml PRP 5 52 weeks
   HA 88 51.5 54.50   0.2 mg HA 5 52 weeks
   PRP + HA 96 46.5 52.10   8 ml PRP + 0.2 mg HA 5 52 weeks
   Placebo 72 56.2 58.30   NM 5 52 weeks
Rahimzadeh, 2018, Iran KL grade I–II PRP 21 65.5 47.60   7 ml PRP 1 26 weeks
   Placebo 21 64.3 52.40 28.6 7 ml 25% dextrose 1 26 weeks
McAlindon, 2017, American ACR criteria; KL grade II–III Corticosteroid 70 59.1 47.10 28.3 4 mg corticosteroid 8 2 years
   Placebo 70 57.2 45.70 30.8 1 ml saline 8 2 years
Tammachote, 2016, Thailand ACR criteria HA 50 62.6 14.00 31.7 6 ml HA 1 26 weeks
   Corticosteroid 49 61 26.00   40 mg TA 1 26 weeks
Cole, 2016, American KL grade I–III PRP 49 55.9 56.00   4 ml PRP 3 52 weeks
   HA 50 56.8 60.00 27.4 16 mg 3 52 weeks
Paterson, 2016, Australia ACR criteria; KL grade II–III PRP 11 49.9 72.73 29 3 ml PRP 1 12 weeks
   HA 10 52.7 70.00 27.9 3 ml HA 1 12 weeks
Lana, 2016, American KL grade I–III HA 36 60 91.70 30.9 20 mg HA 3 52 weeks
   PRP 36 60.9 80.60 28.2 5 ml PRP 3 52 weeks
   PRP + HA 33 62 81.80 27.4 20 mg HA + 5 ml PRP 3 52 weeks
Askari, 2016, Iran KL grade II–III Corticosteroid 69   17.40 29.2 2 cc HA 1 13 weeks
   HA 71   12.70   40 mg corticosteroid 1 13 weeks
Forogh, 2016, Iran KL grade II-III PRP 24 59.1 29.20   5 ml PRP 1 26 weeks
   Corticosteroid 24 61.1 37.50 75.8 40 mg corticosteroid 1 26 weeks
Filardo, 2015, American KL grade I–III PRP 94 53.3 63.80 75.8 5 ml PRP 3 52 weeks
   HA 89 57.6 58.40 26.6 2 ml HA 3 52 weeks
Rayegani, 2014, Iran ACR criteria; KL grade I–IV PRP 31 58.1 6.50 26.9 4–6 ml PRP 2 26 weeks
   Placebo 31 54.7 6.50 28.2 NM NM 26 weeks
Patel, 2013, India ACR criteria; Ahlbäck grade I–II PRP 27 53.1 40.70 27.3 8 ml PRP 1 26 weeks
   Placebo 23 53.7 26.00 26.3 8 ml saline 1 26 weeks
Filardo, 2012, Italy KL grade I–III PRP 54 55 68.50 26.2 5 ml PRP 3 52 weeks
   HA 55 58 56.40 27 NM 3 52 weeks
Huang, 2011, China ACR criteria; KL grade II––III HA 100 65.9 26.00 26 20 mg HA 5 25 weeks
   Placebo 100 64.2 22.00 25.7 2 ml saline 5 25 weeks
Diracoglu, 2009, Turkey ACR criteria; KL grade II–III HA 40    25.4 NM 1 26 weeks
   Placebo 20     NM 1 26 weeks
Lundsgaard, 2008, Denmark KL grade I–IV HA 84 68.8 42.9   2 ml HA 4 52 weeks
   Placebo 84 69.6 47.60 29.6 2 ml saline 4 52 weeks
Ubuku, 2004, Turkey ACR criteria HA 20 52.6 30.00 29.3 2 ml HA 1 8 weeks
   Placebo 10 57.6 0.00   2 ml saline 1 8 weeks
Altman, 2004, American ACR criteria HA 172 62.9 54.00   60 mg HA 1 26 weeks
   Placebo 174 63.3 36.00   3 ml 0.9% saline 1 26 weeks
Karlsson, 2002, Sweden Ahlbäck grade I–II HA 76   35.00   4.5 ml HA 3 52 weeks
   Placebo 57   39.00   3 ml saline 3 52 weeks
  1. HA hyaluronic acid, PRP platelet-rich plasma, ACR American College of Rheumatology, KL Kellgren and Lawrence, NM not mentioned, TA triamcinolone acetonide